Mark Newman is a reporter for Mountain News. He specializes in medicine and healthcare, focusing on topics such as endocrinology, diet and nutrition, aging, and wellness programs, with an interest in both regional and world news. Mark's work has been featured in numerous publications including the Toronto Star, Fast Company, and Scuba Diver Magazine.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Mark Newman's coverage is predominantly focused on local events and community-related topics in Hamilton, Ontario. He covers a wide range of themes including family & relationships, education, culture & society, healthcare & pharmaceutical.
To effectively reach out to Mark with pitches or story ideas, consider offering content related to local community events, educational initiatives in the area, healthcare developments impacting the region, or stories reflecting cultural and societal aspects of Hamilton. Pitches related to advocacy for local issues or retail businesses within the community may also resonate with his coverage interests.
This information evolves through artificial intelligence and human feedback. Improve this profile .
People who lost weight with GLP-1s tended to log fewer daily steps [VIDEO]:
By: Mark Newman
Filmed at DTW 2026, two panel discussions explore the rise of AI-native and autonomous networks, and their role in transforming telecom operations.
By: Mark Newman
On July 15, the Endocrine Society joined 37 professional medical, patient advocacy, and research organizations to endorse a National Strategy to Close the Women's Health Gap.
By: Mark Newman
On July 14, the Centers for Medicare & Medicaid Services (CMS) released the CY 2027 Medicare Physician Fee Schedule (MPFS) proposed rule. Below are some specific areas of interest for endocrinologists, which we will comment on:
By: Mark Newman
The local flower industry would be particularly hard hit by threatened 50 per cent U.S. tariffs.
By: Mark Newman
Popular diabetes and weight-loss medications known as GLP-1 receptor agonists do not increase the risk of cancer in patients with endogenous Cushing's syndrome, according to a comprehensive nationwide study titled, “ ,” and published in The Journal of Clinical Endocrinology & Metabolism . The findings offer critical clinical reassurance for a highly vulnerable patient population prone to both severe metabolic disorders and elevated cancer risks.
By: Mark Newman
Testosterone treatment may improve body composition, glucose metabolism and sexual desire in some older men at high risk of type 2 diabetes, but an ENDO 2026 study by Gary Wittert, MBBch, MD, finds these benefits require engagement in a lifestyle program.
By: Mark Newman
The outstanding ENDO 2026 in Chicago, Ill., is now but a fond memory. Our hardworking member volunteers and staff who organized and executed the meeting can take a well-deserved break. But only a short break.
Artificial intelligence (AI) is steadily moving from novelty to necessity in medicine, and endocrinology is no exception. The ENDO 2026 session “Artificial Intelligence in Endocrinology: Practical Uses, Lessons Learned, and What Comes Next” showed attendees that AI is here, and those who wait too long to engage with it may find themselves playing catch-up.
By: Mark Newman
Medical advances in diagnostic screening and personalized therapies have drastically reduced the early mortality risk for patients with acromegaly, bringing their life expectancy close to that of the general population, according to a comprehensive review titled “ ,” and recently published in The Journal of Clinical Endocrinology & Metabolism
